Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

/PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Kronos Bio ,Jorge Dimartino ,Tony Lialin ,Jeffrey Miller ,Marni Kottle ,Sheryl Seapy ,Claudia Styslinger ,Invivoscribe Inc ,Exchange Commission ,Clinical Development At Kronos Bio ,Drug Administration ,Kronos Bio Inc ,Prnewswire Kronos Bio Inc ,Nasdaq ,Premarket Approval ,New Drug Application ,Clinical Development ,San Mateo ,Improving Lives ,Private Securities Litigation Reform Act ,Quarterly Report ,Bio Contacts ,Commercial Officer ,Invivoscribe ,Nc ,